NYC Healthcare News



biOasis commences research agreement with NRC

January 05, 2016

"ASSERT, as it was designed to do, taught us several key findings," stated Kenneth Lebioda, Senior Vice President Business & Corporate Development of Resverlogix. "We now understand with greater clarity that RVX-208 works better in high risk patients with low HDL and that certain doses have far greater effect in promoting markers of reverse cholesterol transport (RCT). After careful analysis of all the data we also found that when RVX-208 is used with certain statins we see significant reductions in liver signals such as ALTs while still maintaining very good efficacy. These key findings have helped us immensely in designing a more powerful, accurate and targeted ASSURE Phase 2b trial.  In terms of business development this new patent filing greatly expands the scope of our commercial program," Lebioda added.  

SOURCE Resverlogix Corp.